Global Information
회사소개 | 문의

두경부암 : 파이프라인 리뷰

Head And Neck Cancer - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 351248
페이지 정보 영문 2001 Pages
가격
US $ 2,500 ₩ 2,859,700 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,719,500 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,579,200 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


두경부암 : 파이프라인 리뷰 Head And Neck Cancer - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 2001 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

두경부암이란 두부 혹은 경부(비강, 부비동, 입술, 입, 침샘, 목 또는 후두) 영역에서 발생하는 암입니다. 두경부암의 일반적인 증상에는 지속적인 목 통증, 삼킴 통증과 곤란, 지속적인 쉰 목소리와 변성, 귀 통증, 입안이나 목 출혈 등이 있습니다. 화학요법이나 방사선 치료로 관리합니다.

두경부암(Head and neck Cancer) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관에 의해서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 등의 정보를 전해드립니다.

서론

두경부암 개요

치료제 개발

두경부암 : 치료제 평가

두경부암 치료제 개발 참여 기업

약제 개요

두경부암 : 휴지중인 프로젝트

두경부암 : 개발이 중지된 제품

두경부암 : 제품 개발 마일스톤

부록

도표

LSH 17.06.12

List of Tables

  • Number of Products under Development for Head And Neck Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Head And Neck Cancer - Pipeline by 4SC AG, H2 2018
  • Head And Neck Cancer - Pipeline by AbbVie Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Abion Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2018
  • Head And Neck Cancer - Pipeline by ADC Therapeutics SA, H2 2018
  • Head And Neck Cancer - Pipeline by Admedus Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by Aduro BioTech Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Advaxis Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Head And Neck Cancer - Pipeline by Affimed GmbH, H2 2018
  • Head And Neck Cancer - Pipeline by Alkermes Plc, H2 2018
  • Head And Neck Cancer - Pipeline by Altor BioScience Corp, H2 2018
  • Head And Neck Cancer - Pipeline by Ambrx Inc, H2 2018
  • Head And Neck Cancer - Pipeline by amcure GmbH, H2 2018
  • Head And Neck Cancer - Pipeline by Amgen Inc, H2 2018
  • Head And Neck Cancer - Pipeline by AMI Onco Theranostics LLC, H2 2018
  • Head And Neck Cancer - Pipeline by Apexigen Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Arcus Biosciences Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Argenx SE, H2 2018
  • Head And Neck Cancer - Pipeline by ArQule Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Array BioPharma Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by Astellas Pharma Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
  • Head And Neck Cancer - Pipeline by AstraZeneca Plc, H2 2018
  • Head And Neck Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Bayer AG, H2 2018
  • Head And Neck Cancer - Pipeline by BeiGene Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by Benitec Biopharma Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2018
  • Head And Neck Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by BioLineRx Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2018
  • Head And Neck Cancer - Pipeline by Bionovis SA, H2 2018
  • Head And Neck Cancer - Pipeline by BioNTech AG, H2 2018
  • Head And Neck Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2018
  • Head And Neck Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Head And Neck Cancer - Pipeline by Boston Biomedical Inc, H2 2018

List of Figures

  • Number of Products under Development for Head And Neck Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H2 2018, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 134, 143, 5, 89, 23 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 9, 8, 1, 19, 4 and 1 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Head And Neck Cancer - Overview
  • Head And Neck Cancer - Therapeutics Development
  • Head And Neck Cancer - Therapeutics Assessment
  • Head And Neck Cancer - Companies Involved in Therapeutics Development
  • Head And Neck Cancer - Drug Profiles
  • Head And Neck Cancer - Dormant Projects
  • Head And Neck Cancer - Discontinued Products
  • Head And Neck Cancer - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research